351 related articles for article (PubMed ID: 38632167)
1. Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress.
Liu Y; Li C; Liu H; Tan S
Arch Pharm Res; 2024 Apr; ():. PubMed ID: 38632167
[TBL] [Abstract][Full Text] [Related]
2. HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review).
Li ZN; Luo Y
Oncol Rep; 2023 Jan; 49(1):. PubMed ID: 36367182
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule dual inhibitors targeting heat shock protein 90 for cancer targeted therapy.
Xie X; Zhang N; Li X; Huang H; Peng C; Huang W; Foster LJ; He G; Han B
Bioorg Chem; 2023 Oct; 139():106721. PubMed ID: 37467620
[TBL] [Abstract][Full Text] [Related]
4. Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy.
Ren X; Li T; Zhang W; Yang X
Cells; 2022 Aug; 11(16):. PubMed ID: 36010632
[TBL] [Abstract][Full Text] [Related]
5. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
Powers MV; Workman P
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
[TBL] [Abstract][Full Text] [Related]
6. Hsp90 inhibitors as promising agents for radiotherapy.
Kabakov AE; Kudryavtsev VA; Gabai VL
J Mol Med (Berl); 2010 Mar; 88(3):241-7. PubMed ID: 19946660
[TBL] [Abstract][Full Text] [Related]
7. HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy.
Hwang M; Moretti L; Lu B
Curr Med Chem; 2009; 16(24):3081-92. PubMed ID: 19689285
[TBL] [Abstract][Full Text] [Related]
8. Ganetespib: research and clinical development.
Jhaveri K; Modi S
Onco Targets Ther; 2015; 8():1849-58. PubMed ID: 26244021
[TBL] [Abstract][Full Text] [Related]
9. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).
Solárová Z; Mojžiš J; Solár P
Int J Oncol; 2015 Mar; 46(3):907-26. PubMed ID: 25501619
[TBL] [Abstract][Full Text] [Related]
10. Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
Mumin NH; Drobnitzky N; Patel A; Lourenco LM; Cahill FF; Jiang Y; Kong A; Ryan AJ
BMC Cancer; 2019 Jan; 19(1):102. PubMed ID: 30678647
[TBL] [Abstract][Full Text] [Related]
11. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
[TBL] [Abstract][Full Text] [Related]
12. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise.
Proia DA; Bates RC
Cancer Res; 2014 Mar; 74(5):1294-300. PubMed ID: 24556722
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment.
Talaei S; Mellatyar H; Asadi A; Akbarzadeh A; Sheervalilou R; Zarghami N
Chem Biol Drug Des; 2019 May; 93(5):760-786. PubMed ID: 30697932
[TBL] [Abstract][Full Text] [Related]
14. [Inhibitors of the heat shock protein 90 activity: a novel class of tumor radiosensitizers].
Kabakov AE; Kudriavtsev VA; Makarova IuM
Radiats Biol Radioecol; 2010; 50(5):528-35. PubMed ID: 21261003
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathways: targeting hsp90--who benefits and who does not.
Scaltriti M; Dawood S; Cortes J
Clin Cancer Res; 2012 Sep; 18(17):4508-13. PubMed ID: 22718860
[TBL] [Abstract][Full Text] [Related]
16. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.
Messaoudi S; Peyrat JF; Brion JD; Alami M
Expert Opin Ther Pat; 2011 Oct; 21(10):1501-42. PubMed ID: 21689065
[TBL] [Abstract][Full Text] [Related]
17. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents.
Neckers L; Neckers K
Expert Opin Emerg Drugs; 2002 Oct; 7(2):277-88. PubMed ID: 15989551
[TBL] [Abstract][Full Text] [Related]
18. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
Jensen MR; Schoepfer J; Radimerski T; Massey A; Guy CT; Brueggen J; Quadt C; Buckler A; Cozens R; Drysdale MJ; Garcia-Echeverria C; Chène P
Breast Cancer Res; 2008; 10(2):R33. PubMed ID: 18430202
[TBL] [Abstract][Full Text] [Related]
19. An updated patent review of anticancer Hsp90 inhibitors (2013-present).
Li L; Chen NN; You QD; Xu XL
Expert Opin Ther Pat; 2021 Jan; 31(1):67-80. PubMed ID: 32990109
[TBL] [Abstract][Full Text] [Related]
20. Combination therapies with HSP90 inhibitors against colorectal cancer.
Kryeziu K; Bruun J; Guren TK; Sveen A; Lothe RA
Biochim Biophys Acta Rev Cancer; 2019 Apr; 1871(2):240-247. PubMed ID: 30708039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]